COSCIENS Biopharma Inc. (TSX:CSCI)

COSCIENS Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5.28	7.31	16.39	6.68	50.61	65.3
Cash & Short-Term Investments	5.28	7.31	16.39	6.68	50.61	65.3
Cash Growth	-43.45%	-55.43%	145.48%	-86.80%	-22.50%	169.04%
Accounts Receivable	2.37	1.08	1.88	0.13	0.4	0.88
Other Receivables	-	0.18	0.59	0.16	1.76	2.8
Receivables	2.37	1.26	2.47	0.29	2.16	3.68
Inventory	0.96	1.31	2.69	4.01	0.23	0.07
Prepaid Expenses	1.02	1.4	1.7	0.08	0.43	0.42
Other Current Assets	0.07	0.22	0.73	0.21	2.06	1.35
Total Current Assets	9.69	11.5	23.98	11.27	55.49	70.82
Property, Plant & Equipment	8.75	9.81	10.97	11.65	0.22	0.19
Goodwill	-	-	-	-	-	8.13
Other Intangible Assets	0	-	-	0.01	-	0.63
Long-Term Deferred Tax Assets	-	-	-	0.08	-	-
Other Long-Term Assets	0.21	0.13	0.12	0.75	0.32	0.34
Total Assets	18.85	21.43	35.07	23.75	56.03	80.1

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.54	0.75	2.41	0.28	2.04	0.93
Accrued Expenses	0.27	1.14	2.37	0.73	1.79	1.74
Current Portion of Leases	0.19	0.22	0.27	0.3	0.11	0.13
Current Income Taxes Payable	0	0.12	0.11	-	0.11	0.12
Current Unearned Revenue	-	-	0.12	-	2.95	4.82
Other Current Liabilities	1.25	1.39	1.95	-	0.05	0.03
Total Current Liabilities	2.24	3.61	7.22	1.31	7.04	7.77
Long-Term Leases	1.77	1.93	2.04	1.4	0.07	0.03
Long-Term Unearned Revenue	-	1.06	0.91	-	1.79	1.59
Pension & Post-Retirement Benefits	-	10.98	11.73	-	11.16	17.49
Other Long-Term Liabilities	-	-	-	-	0.19	0.24
Total Liabilities	4.01	17.59	21.91	2.71	20.25	27.12

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	22.63	22.62	22.49	13.52	293.41	293.41
Additional Paid-In Capital	-	-	-	-	90.33	-
Retained Earnings	-9.95	-20.51	-12.11	4.36	-352.08	-334.62
Comprehensive Income & Other	2.17	1.73	2.79	3.16	4.12	94.2
Shareholders' Equity	14.84	3.84	13.16	21.04	35.78	52.99
Total Liabilities & Equity	18.85	21.43	35.07	23.75	56.03	80.1

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.96	2.15	2.31	1.7	0.18	0.16
Net Cash (Debt)	3.32	5.16	14.08	4.98	50.43	65.14
Net Cash Growth	-53.05%	-63.37%	182.79%	-90.13%	-22.58%	170.43%
Net Cash Per Share	3.15	4.89	16.37	8.09	81.58	170.04
Filing Date Shares Outstanding	1	1.06	1.05	0.4	0.4	0.4
Total Common Shares Outstanding	1.06	1.06	1.05	0.4	0.4	0.4
Working Capital	7.45	7.89	16.76	9.96	48.44	63.05
Book Value Per Share	13.98	3.62	12.57	51.98	88.41	130.94
Tangible Book Value	14.84	3.84	13.16	21.03	35.78	44.23
Tangible Book Value Per Share	13.98	3.62	12.57	51.97	88.41	109.30
Machinery	9.98	10.74	10.9	11.98	0.45	0.47
Leasehold Improvements	5.74	5.95	5.64	6.68	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 1, 2026

Data Sources Report a data error